Stay updated with breaking news from Sel hardy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
U.S.-based Eli Lilly and Denmark's Novo Nordisk have struck gold with their weight-loss drugs, sending their shares to stratospheric levels and putting them on par with some high-growth tech stocks. Retail and institutional investors alike have flocked to the two stocks in the past year, as they bet on explosive demand for the companies' obesity drugs, called GLP-1 agonists, in a market that some analysts expect could breach $100 billion. Lilly shares trade 56.17 times the earnings estimates for the next 12 months, while Novo has a price-to-earnings (PE) multiple of 35.84, according to LSEG data. ....
U.S.-based Eli Lilly and Denmark s Novo Nordisk have struck gold with their weight-loss drugs, sending their shares to stratospheric levels and putting them on par with some high-growth tech stocks. . ....
By Medha Singh and Manas Mishra (Reuters) - U.S.-based Eli Lilly and Denmark's Novo Nordisk have struck gold with their weight-loss drugs, sending their shares to stratospheric levels and putting them on par with some high-growth tech stocks. Retai. ....